Adjuvant cytokine treatment of minimal residual disease after surgical therapy in mice carrying HPV16-associated tumours: Cytolytic activity of spleen cells from tumour regressors

Folia Biologica

Volumn 49, Issue 6, 2003, Pages 217-222

  Indrová, Marie ^b   Mikyskova R ^b   Jandlova T ^b   Vonka, V ^a   Bubenik J ^b   Bieblova J ^b  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

Cytotoxic effectors; Gene therapy; HPV16; IL 2; Minimal residual tumour disease

Indexed keywords

CYTOKINE; IMMUNOLOGICAL ADJUVANT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CELL ACTIVITY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; EFFECTOR CELL; MALE; MINIMAL RESIDUAL DISEASE; MOUSE; NATURAL KILLER CELL; NONHUMAN; POSTOPERATIVE PERIOD; SPLEEN CELL; TARGET CELL; TUMOR CELL LINE; TUMOR CLASSIFICATION; TUMOR GROWTH; TUMOR REGRESSION; TUMOR REJECTION; VERRUCOUS CARCINOMA; VIRUS CARCINOGENESIS; WART VIRUS;

ANIMALIA; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPES;

EID: 0942287882     PISSN: 00155500     EISSN: 25337602     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Bubeník, J. (2002) Animal models for development of therapeutic HPV16 vaccines. Int. J. Oncol. 20, 207-212.
2. Bubeník, J. (2003) MHC class I downregulation and tumour immunotherapy. Oncol. Rep. 10, 2005-2008.
3. Bubeník, J., Lotzová, E., Indrová, M. Šímová, J., Jandlová, T., Bubeníková, D. (1992) Use of IL-2 gene transfer in local immunotherapy of cancer. Cancer Lett. 62, 257-262.
4. Bubeník, J., Zeuthen J., Indrová, M., Bubeníková, D., Šímová, J. (1994) Kinetics and function of peritoneal exudate cells during local IL-2 gene therapy of cancer. Int. J. Oncol. 4, 13-16.
5. Bubeník, J., Šímová, J., Hájková, R., Sobota, V., Jandlová, T., Šmahel, M., Sobotková. E., Vonka, V. (1999) Interleukin-2 gene therapy of residual disease in mice carrying tumours induced by HPV 16. Int. J. Oncol. 14, 593-597.
6. Bubeník, J., Mikyšková, R., Vonka, V., Mendoza, L., Šímová, J., Šmahel, M., Indrová, M. (2003) Interleukin 2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papilloma virus type 16. Vaccine 21, 890-896.
7. Goldie, H., Butler, C. H., Anderson, M. M. (1953) Growth characteristic of free C1498 (granulocytic leukaemia) tumour cells in the peritoneal fluid and the blood of C57 mice. Cancer Res. 13, 125-129.
8. Indrová, M., Bubeník, J., Šímová, J., Bieblová, J., Jandlová, T., Šmahel, M., Vonka, V., Glazman-Kusnierczyk, H., Pajtasz-Piasecka, E., Radzikowski, C., Mikyšková, R. (2001) Chemoimmunotherapy of cancer: potentiated effectiveness of granulocyte-macrophage colony-stimulating factor and ifosfamide derivative CBM-4A. Oncol. Rep. 8, 1371-1374.
9. Indrová, M., Bubeník, J., Mikyšková, R., Vonka, V., Šmahel, M., Žák, R., Šímová, J., Bieblová, J., Mendoza, L., Jandlová, T. (2002) Tumour inhibitory and antimetastatic effect of IL-2 in mice carrying MHC class I tumours of HPV 16 origin. Int. J. Oncol. 20, 643-646.
10. - tumours: effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines. Int. J. Oncol. 22, 691-695.
11. Jinoch, P., Žák, R., Janoušková, O., Kunke, O., Ritich, S., Dušková, M., Sobotková, E., Marinov, I., Andělová, M., Šmahel, M., Vonka, V. (2003) Immunization with live HPV-16-transformed mouse cells expressing the herpes simplex thymidine-kinase and either GM-CSF or IL-2. Int. J. Oncol. 23, 775-783.
12. LaBelle, J. L., Truit, R. L. (2002) Characterization of murine NKT cell tumor previously described as an acute myelogenous leukemia. Leuk. Lymphoma 43, 1637-1644.
13. Lin, K. Y., Guarnieri, F. G., Staveley O'Carroll, K. F., Levitsky, H. J., August, J. T., Pardoll, D. M., Wu, T. C. (1996) Treatment of established tumours with a novel vaccine that enhances major histocompatibility class II presentation of tumour antigen. Cancer Res. 56, 21-26.
14. Mikyšková, R., Bubeník, J., Mendoza, L., Vonka, V., Šmahel, M., Šímová, J., Jandlová, T. (2001) Local cytokine treatment of HPV16-associated tumours results in inhibition of their lung metastases. Clin. Exp. Metastasis 18, 581-587.
15. Mikyšková, R., Bieblová, J., Šímová, J., Indrová, M., Jandlová, T., Vonka, V., Šmahel, M., Bubeník, J., Mendoza, L. (2003a Local IFNγ therapy of HPV16-associated tumours. Folia Biol. (Praha ) 49, 26-32.
16. Mikyšková, R., Indrová, M. Šímová, J., Jandlová, T., Bieblová, J., Jinoch J., Bubeník, J., Vonka, V. (2003b) Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: cytokine and gene therapy with IL-2 and GM-CSF. Int. J. Oncol., in press.
17. Offringa, R., van der Burg, S. H., Ossendorp, F., Toes, R. E., Melief, C. J. (2000) Design and evaluation of antigen-specific vaccination strategies against cancer. Curr. Opin. Immunol. 12, 576-582.
18. Šmahel, M., Sobotková, E., Bubeník, J., Šímová, J., Žák, R., Ludvíková, V., Hájková, R., Kovařík, J., Jelínek, F., Povýšil, C., Marinov, J., Vonka, V. (2001) Metastatic MHC class I-negative mouse cells derived by transformation with human papillomavirus type 16. Br. J. Cancer 84, 374-380.
19. Vlk, V., Rössner, P., Indrová, M., Bubeník, J., Sobota, V. (1998) Interleukin-2 gene therapy of surgical minimal residual tumour disease. Int. J. Cancer 76, 115-119.
20. Wigzell, H., Ramstedt, U. (1986) Natural killer cells. In: Cellular Immunology, ed. Weir, M. M., pp. 601-609, Blackwell Scientific Publ., Oxford.